Report of the Directors
Business Review

Animal Testing

In common with all companies developing and marketing chemical substances, Johnson Matthey must comply with international legislation to make toxicity information available to assure product safety for humans, wildlife and the environment. We are committed to ethical principles of animal protection and our corporate policy is based on the following principles:

Johnson Matthey has embraced the ‘3Rs’ approach in relying on properly validated alternative methods which reduce, refine or replace the use of animal testing. Therefore we now place emphasis firstly on applying the latest integrated testing strategies (e.g. in vitro assays, computer modelling of effects and in vivo test waiving approaches). New techniques are continually tracked and implemented as they become endorsed by regulatory bodies.
If, after confirming that suitable data does not already exist, in vivo studies are unavoidable, we always seek to limit new testing and avoid unnecessary studies by undertaking collaborative work with industrial partners.
It is ensured that any studies comply with all applicable laws, regulations, licensing and welfare codes.
Johnson Matthey only uses fully accredited contract research organisations and does not undertake any in house toxicity testing.
As a fundamental operating principle, our oversight procedures require that our businesses commission no vertebrate animal studies until a justification has been carefully considered and approved at group level.

The group does not manufacture any cosmetics or consumer goods and testing is therefore aligned to regulatory requirements for industrial substances. Any testing required as a result of registration requirements imposed under the EU REACH regulation is minimised by working within industry consortia.

Johnson Matthey shares current societal and political concern over animal testing and we only commission studies when mandated by law and if no alternatives exist. During the year, Johnson Matthey has continued to provide financial sponsorship for external educational programmes aimed at increasing awareness of 3Rs alternative approaches. We remain optimistic that advances in toxicology science will enable us to further reduce in vivo testing while continuing to safeguard human health and the environment.

Back to top